Sign in Subscribe

Merck Buys Terns Pharmaceuticals for $6.7 Billion to Boost Blood Cancer Pipeline with Promising CML Drug

Merck is buying Terns Pharmaceuticals for $6.7 billion to add TERN-701, a promising new oral drug for chronic myeloid leukemia (CML). The move strengthens its cancer pipeline as Keytruda patent expiry nears in 2028.

Merck Buys Terns Pharmaceuticals for $6.7 Billion to Boost Blood Cancer Pipeline with Promising CML Drug
Credit: Michael Nagle/Bloomberg
Already have an account? Sign in.